Literature DB >> 27389542

IL-2, the next best thing in chronic GVHD therapy?

Lauren M Curtis1, Steven Z Pavletic1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27389542      PMCID： PMC4937357          DOI： 10.1182/blood-2016-05-711796

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

1.  Age-dependent incidence, time course, and consequences of thymic renewal in adults.

Authors:  Frances T Hakim; Sarfraz A Memon; Rosemarie Cepeda; Elizabeth C Jones; Catherine K Chow; Claude Kasten-Sportes; Jeanne Odom; Barbara A Vance; Barbara L Christensen; Crystal L Mackall; Ronald E Gress
Journal:  J Clin Invest       Date:  2005-03-17       Impact factor: 14.808

2.  Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.

Authors:  Daniel Wolff; Michael Schleuning; Stephanie von Harsdorf; Ulrike Bacher; Armin Gerbitz; Michael Stadler; Francis Ayuk; Alexander Kiani; Rainer Schwerdtfeger; Georgia B Vogelsang; Guido Kobbe; Martin Gramatzki; Anita Lawitschka; Mohamad Mohty; Steven Z Pavletic; Hildegard Greinix; Ernst Holler
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-26       Impact factor: 5.742

3.  Interleukin-2 and regulatory T cells in graft-versus-host disease.

Authors:  John Koreth; Ken-ichi Matsuoka; Haesook T Kim; Sean M McDonough; Bhavjot Bindra; Edwin P Alyea; Philippe Armand; Corey Cutler; Vincent T Ho; Nathaniel S Treister; Don C Bienfang; Sashank Prasad; Dmitrios Tzachanis; Robin M Joyce; David E Avigan; Joseph H Antin; Jerome Ritz; Robert J Soiffer
Journal:  N Engl J Med       Date:  2011-12-01       Impact factor: 91.245

4.  Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.

Authors:  Sally Arai; Mukta Arora; Tao Wang; Stephen R Spellman; Wensheng He; Daniel R Couriel; Alvaro Urbano-Ispizua; Corey S Cutler; Andrea A Bacigalupo; Minoo Battiwalla; Mary E Flowers; Mark B Juckett; Stephanie J Lee; Alison W Loren; Thomas R Klumpp; Susan E Prockup; Olle T H Ringdén; Bipin N Savani; Gérard Socié; Kirk R Schultz; Thomas Spitzer; Takanori Teshima; Christopher N Bredeson; David A Jacobsohn; Robert J Hayashi; William R Drobyski; Haydar A Frangoul; Görgün Akpek; Vincent T Ho; Victor A Lewis; Robert Peter Gale; John Koreth; Nelson J Chao; Mahmoud D Aljurf; Brenda W Cooper; Mary J Laughlin; Jack W Hsu; Peiman Hematti; Leo F Verdonck; Melhelm M Solh; Maxim Norkin; Vijay Reddy; Rodrigo Martino; Shahinaz Gadalla; Jenna D Goldberg; Philip L McCarthy; José A Pérez-Simón; Nandita Khera; Ian D Lewis; Yoshiko Atsuta; Richard F Olsson; Wael Saber; Edmund K Waller; Didier Blaise; Joseph A Pidala; Paul J Martin; Prakash Satwani; Martin Bornhäuser; Yoshihiro Inamoto; Daniel J Weisdorf; Mary M Horowitz; Steven Z Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2014-10-30       Impact factor: 5.742

5.  Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease.

Authors:  Yoshihiro Inamoto; Barry E Storer; Stephanie J Lee; Paul A Carpenter; Brenda M Sandmaier; Mary E D Flowers; Paul J Martin
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

6.  Duration of immunosuppressive treatment for chronic graft-versus-host disease.

Authors:  Betty L Stewart; Barry Storer; Jan Storek; H Joachim Deeg; Rainer Storb; John A Hansen; Frederick R Appelbaum; Paul A Carpenter; Jean E Sanders; Hans-Peter Kiem; Richard A Nash; Effie W Petersdorf; Carina Moravec; A James Morton; Claudio Anasetti; Mary E D Flowers; Paul J Martin
Journal:  Blood       Date:  2004-08-03       Impact factor: 22.113

Review 7.  Current issues in chronic graft-versus-host disease.

Authors:  Gérard Socié; Jerome Ritz
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

8.  Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.

Authors:  John Koreth; Haesook T Kim; Kyle T Jones; Paulina B Lange; Carol G Reynolds; Marie J Chammas; Katherine Dusenbury; Jennifer Whangbo; Sarah Nikiforow; Edwin P Alyea; Philippe Armand; Corey S Cutler; Vincent T Ho; Yi-Bin Chen; David Avigan; Bruce R Blazar; Joseph H Antin; Jerome Ritz; Robert J Soiffer
Journal:  Blood       Date:  2016-04-12       Impact factor: 22.113
  8 in total
  2 in total

Review 1.  New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions.

Authors:  Nathaniel Edward Bennett Saidu; Chiara Bonini; Anne Dickinson; Magdalena Grce; Marit Inngjerdingen; Ulrike Koehl; Antoine Toubert; Robert Zeiser; Sara Galimberti
Journal:  Front Immunol       Date:  2020-10-09       Impact factor: 7.561

2.  Bone Marrow Regulatory T Cells Are a Unique Population, Supported by Niche-Specific Cytokines and Plasmacytoid Dendritic Cells, and Required for Chronic Graft-Versus-Host Disease Control.

Authors:  Jemma Nicholls; Benjamin Cao; Laetitia Le Texier; Laura Yan Xiong; Christopher R Hunter; Genesis Llanes; Ethan G Aguliar; Wayne A Schroder; Simon Phipps; Jason P Lynch; Huimin Cao; Shen Y Heazlewood; Brenda Williams; Andrew D Clouston; Christian M Nefzger; Jose M Polo; Susan K Nilsson; Bruce R Blazar; Kelli P A MacDonald
Journal:  Front Cell Dev Biol       Date:  2021-09-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.